Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.86 by $0.22, FiscalAI reports.
Rocket Pharmaceuticals Stock Up 0.8%
Shares of RCKT traded up $0.03 during trading hours on Monday, hitting $3.64. The stock had a trading volume of 1,354,429 shares, compared to its average volume of 2,750,771. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a 50 day simple moving average of $3.33 and a 200-day simple moving average of $3.61. The firm has a market capitalization of $397.45 million, a P/E ratio of -1.95 and a beta of 0.47. Rocket Pharmaceuticals has a 1-year low of $2.53 and a 1-year high of $5.45.
Insiders Place Their Bets
In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 55,684 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total value of $172,063.56. Following the transaction, the chief executive officer owned 1,061,724 shares in the company, valued at approximately $3,280,727.16. This represents a 4.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 66,083 shares of company stock worth $207,531. 21.30% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Rocket Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. MPM Bioimpact LLC lifted its holdings in shares of Rocket Pharmaceuticals by 141.2% in the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company's stock valued at $9,563,000 after purchasing an additional 2,284,816 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in Rocket Pharmaceuticals by 690.8% during the second quarter. Qube Research & Technologies Ltd now owns 1,548,262 shares of the biotechnology company's stock worth $3,793,000 after purchasing an additional 1,352,469 shares during the last quarter. Millennium Management LLC grew its position in Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company's stock worth $11,639,000 after purchasing an additional 1,221,554 shares in the last quarter. Opaleye Management Inc. purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at about $3,352,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Rocket Pharmaceuticals by 73.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,097,033 shares of the biotechnology company's stock worth $6,836,000 after buying an additional 889,231 shares during the last quarter. 98.39% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research firms recently commented on RCKT. Chardan Capital reaffirmed a "buy" rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday, May 11th. Weiss Ratings upgraded Rocket Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered shares of Rocket Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $8.71.
Check Out Our Latest Report on RCKT
About Rocket Pharmaceuticals
(
Get Free Report)
Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.
The company's pipeline comprises multiple product candidates in various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Rocket Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.
While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
